Search
Selected Filter
Filter Results
Displaying 221–230 of 541 news results
-
Sep 22, 2021
In the PressInitial programs will focus on treatments for rare pediatric blinding conditions. Company formed to advance the work of scientific cofounders Dr. Jean Bennett, Junwei Sun and Dr. Eric Pierce.
-
Sep 21, 2021
Foundation NewsCourse Title: A Review and Comparison of Different Forms of Age-Related and Inherited Macular Degenerations
-
Sep 10, 2021
Apellis to Seek FDA Approval of its Dry AMD Drug
Research NewsKnown as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Sep 9, 2021
Optogenetics: Hope for Vision Restoration for Advanced Retinal Diseases
Research NewsEarly, encouraging results from two human studies — trials launched by Bionic Sight and GenSight — are putting optogenetic therapies in the spotlight for patients with advanced vision loss from retinal conditions.
-
Sep 7, 2021
Foundation NewsThis September 16th celebratory episode features the world premiere of “Dis Education” – an original collaboration by Lachi and Apl.de.Ap.
-
Aug 4, 2021
Pediatric Ophthalmologists Target Inherited Retinal Diseases
In the PressNew opportunities continue to develop in an evolving landscape.
-
Jul 20, 2021
Statement from Ben Yerxa, PhD, about Paralympian Becca Meyers
Foundation NewsThe Foundation believes that all people with disabilities should receive the accommodations necessary for their inclusion in all facets of society, especially when an individual may be unfamiliar with the area.
-
Jul 19, 2021
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
Research NewsWhile the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
Jul 12, 2021
BioBonds in New York Times: Ask Congress to Support Biomedical Research for Treatments and Cures
In the PressKaren Petrou invented a new funding model for curing blindness. Proposed legislation aims to apply it to medical research more generally.
-
Jun 25, 2021
Research NewsThe company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.